Potential Reduction in Adverse Events and Cost with Novel Anticoagulants among Patients with Acute Limb Ischemia

Figure 1

Cumulative incidence plot of the primary composite endpoint including adverse cardiovascular and limb events. (i) The projected cumulative incidence was calculated by first multiplying the observed cumulative hazard by the hazard ratio, its lower confidence interval (CI) limit, and its upper confidence interval limit reported in the COMPASS trial subgroup analysis (, 95% CI: 0.56-0.85 [8]). It was then transformed to the projected cumulative incidence.